StockNews.com Begins Coverage on Community Financial (NASDAQ:TCFC)

RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its target price cut by HC Wainwright from $43.00 to $41.00 in a report issued on Friday morning, The Fly reports. Several other brokerages have also recently commented on RAPT. JPMorgan Chase & Co. cut their price target on shares of RAPT Therapeutics from $48.00 to $42.00 and […]

Related Keywords

Switzerland ,Swiss , ,Goldman Sachs Group ,Dimensional Fund Advisors ,Nasdaq ,Metlife Investment Management ,Swiss National Bank ,Cantor Fitzgerald ,Jpmorgan Chase Co ,Rapt Therapeutics Inc ,Get Rating ,Director Wendye Robbins ,National Bank ,Life Investment Management ,Fund Advisors ,South San Francisco ,Rapt Therapeutics ,Nasdaq Rapt ,Strapt ,Medical ,Lower Price Target ,Hc Wainwright ,